{"id":"https://openalex.org/W57783008","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.2074","title":"Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM)","display_name":"Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM)","publication_year":2008,"publication_date":"2008-05-20","ids":{"openalex":"https://openalex.org/W57783008","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.2074","mag":"57783008"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2008.26.15_suppl.2074","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.2074","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.26.15_suppl.2074","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"R. Maron","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. Maron","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014505996","display_name":"James J. Vredenburgh","orcid":"https://orcid.org/0000-0002-2935-6057","observed_orcids":["https://orcid.org/0000-0002-2935-6057"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. J. Vredenburgh","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002201007","display_name":"Annick Desjardins","orcid":"https://orcid.org/0000-0003-3869-8283","observed_orcids":["https://orcid.org/0000-0003-3869-8283"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Desjardins","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059965175","display_name":"David A. Reardon","orcid":"https://orcid.org/0000-0001-6674-0157","observed_orcids":["https://orcid.org/0000-0001-6674-0157"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. A. Reardon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069314279","display_name":"Jennifer A. Quinn","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. A. Quinn","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021296578","display_name":"Jeremy N. Rich","orcid":"https://orcid.org/0000-0001-7845-5302","observed_orcids":["https://orcid.org/0000-0001-7845-5302"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. N. Rich","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043001715","display_name":"Sridharan Gururangan","orcid":"https://orcid.org/0000-0003-0311-7127","observed_orcids":["https://orcid.org/0000-0003-0311-7127"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Gururangan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103725465","display_name":"Stephanie Ann Wagner","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. A. Wagner","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108520640","display_name":"Michael E. Salacz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. E. Salacz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5057371623","display_name":"Henry S. Friedman","orcid":"https://orcid.org/0000-0001-7588-032X","observed_orcids":["https://orcid.org/0000-0001-7588-032X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. S. Friedman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":14,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"26","issue":"15_suppl","first_page":"2074","last_page":"2074"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/recurrent-glioblastoma","display_name":"recurrent glioblastoma","score":0.9639999866485596},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9950000047683716},{"id":"https://openalex.org/keywords/vegf-inhibition","display_name":"VEGF inhibition","score":0.8320000171661377},{"id":"https://openalex.org/keywords/mgmt-promoter-methylation","display_name":"MGMT promoter methylation","score":0.8019999861717224},{"id":"https://openalex.org/keywords/temozolomide-resistance","display_name":"temozolomide resistance","score":0.9020000100135803},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.6549999713897705},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.6330000162124634},{"id":"https://openalex.org/keywords/hemorrhagic-pancreatitis","display_name":"hemorrhagic pancreatitis","score":0.628000020980835},{"id":"https://openalex.org/keywords/pneumocystis-jirovecii-pneumonia","display_name":"Pneumocystis carinii pneumonia","score":0.8830000162124634}],"concepts":[{"id":"https://openalex.org/C2777389519","wikidata":"https://www.wikidata.org/wiki/Q425088","display_name":"Temozolomide","level":3,"score":0.9674957990646362},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9311075806617737},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.8481857776641846},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5986371636390686},{"id":"https://openalex.org/C2780964509","wikidata":"https://www.wikidata.org/wiki/Q416975","display_name":"Dacarbazine","level":3,"score":0.58591628074646},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5817955732345581},{"id":"https://openalex.org/C2780259306","wikidata":"https://www.wikidata.org/wiki/Q412197","display_name":"Irinotecan","level":4,"score":0.4750009775161743},{"id":"https://openalex.org/C2777025900","wikidata":"https://www.wikidata.org/wiki/Q29725","display_name":"Vascular endothelial growth factor","level":3,"score":0.4208259880542755},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3918474316596985},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3580934703350067},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.17166095972061157},{"id":"https://openalex.org/C167734588","wikidata":"https://www.wikidata.org/wiki/Q4356503","display_name":"VEGF receptors","level":2,"score":0.10282567143440247},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.06405618786811829}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2008.26.15_suppl.2074","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.2074","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.26.15_suppl.2074","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9922999739646912,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2507626418","https://openalex.org/W2473819352","https://openalex.org/W2132697290","https://openalex.org/W4388473705","https://openalex.org/W2037400652","https://openalex.org/W3158211927","https://openalex.org/W1978884813","https://openalex.org/W3186337251","https://openalex.org/W2063164866","https://openalex.org/W2318071852"],"abstract_inverted_index":{"2074":[0],"Background:":[1],"The":[2,23,78,121],"survival":[3,42],"for":[4,94,214],"patients":[5,95,100,156,178,183],"with":[6,11,64,86,96,101,126,129,137],"recurrent":[7,60,97,102,202],"GBM":[8,31,61,103,203],"is":[9,50,197,210],"dismal,":[10],"<":[12],"10%":[13],"alive":[14],"at":[15,83,88],"two":[16],"years.":[17],"GBMs":[18],"are":[19],"highly":[20],"vascular":[21,25],"tumors.":[22],"more":[24],"endothelial":[26],"growth":[27],"factor":[28],"(VEGF)":[29],"a":[30,44,51,159,211],"contains,":[32],"the":[33,35,176],"worse":[34],"prognosis.":[36],"An":[37],"antibody":[38,53],"to":[39,54,71,117,185,190],"VEGF":[40,55],"improved":[41],"in":[43],"xenograft":[45],"model":[46],"of":[47,175],"GBM.":[48,98],"Bevacizumab":[49],"humanized":[52],"and":[56,113,134,151,168,195,204],"was":[57,144],"active":[58,199],"against":[59,201],"when":[62],"combined":[63,80],"irinotecan.":[65],"Daily":[66,193,208],"temozolomide":[67,73,82,194,209],"may":[68],"overcome":[69],"resistance":[70],"5-day":[72,118],"by":[74],"depleting":[75],"MGMT.":[76],"Methods:":[77],"trial":[79],"daily":[81],"50":[84],"mg/m2/day":[85],"bevacizumab":[87,196],"10":[89],"mg/kg":[90],"every":[91],"14":[92],"days":[93],"Thirty-two":[99],"were":[104],"enrolled":[105],"between":[106],"07/18/07\u201309/02/07,":[107],"all":[108],"had":[109,123,158,165,171],"received":[110],"radiation":[111],"therapy":[112],"20/32":[114],"(63%)":[115],"progressed":[116],"temozolomide.":[119],"Results:":[120],"treatment":[122],"acceptable":[124,206],"toxicity":[125],"one":[127,135],"patient":[128,136],"grade":[130,138,147],"4":[131],"hemorrhagic":[132],"pancreatitis,":[133],"5":[139],"pneumocystis":[140],"carinii":[141],"pneumonia.":[142],"There":[143],"no":[145,152],">":[146],"3":[148],"hematologic":[149],"toxicity,":[150],"CNS":[153],"hemorrhages.":[154],"Twelve":[155],"(37.5%)":[157,164],"partial":[160],"response,":[161],"another":[162],"12":[163],"stable":[166],"disease,":[167],"8/32":[169],"(25%)":[170],"progressive":[172],"disease.":[173],"Eighteen":[174],"32":[177],"remain":[179],"on":[180],"study.":[181],"Two":[182],"requested":[184],"come":[186],"off":[187],"study":[188],"secondary":[189],"fatigue.":[191],"Conclusions:":[192],"an":[198],"regimen":[200],"has":[205],"toxicity.":[207],"good":[212],"platform":[213],"combination":[215],"regimens.":[216],"Author":[217],"Disclosure":[218],"Employment":[219],"or":[220,223],"Leadership":[221],"Consultant":[222],"Advisory":[224],"Role":[225],"Stock":[226],"Ownership":[227],"Honoraria":[228],"Research":[229],"Expert":[230],"Testimony":[231],"Other":[232],"Remuneration":[233],"Genentech":[234,235,236,237]},"counts_by_year":[{"year":2014,"cited_by_count":1},{"year":2012,"cited_by_count":3}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2025-10-10T00:00:00"}